The Rise of ASCs and What It Means for Medical Device Sales

Ambulatory surgery centers have been around since the 1970s. They are not new. What is new is the speed and scale at which surgical procedures are migrating from hospital inpatient and outpatient departments to freestanding ASCs — and the degree to which this migration is reshaping the medical device sales industry from the ground up.

In 2026, there are more than 6,300 Medicare-certified ASCs in the United States, and hundreds more that operate outside the Medicare system. CMS continues to add procedures to the ASC-approved list, including total joint replacements that were exclusively hospital procedures just a few years ago. Private equity is pouring capital into ASC development and acquisition. Orthopedic surgeons, spine surgeons, and sports medicine specialists are building their own centers or buying into existing ones. The shift is structural, not cyclical, and it is not slowing down.

If you sell medical devices — implants, biologics, instrumentation, capital equipment — this matters. The ASC market operates differently from the hospital market in almost every way that affects your sales process, your margins, your logistics, and your relationships. This article covers what is driving ASC growth, how ASC purchasing works, and what medical device sales professionals need to do differently to win in this segment.

Why ASCs Are Growing This Fast

ASC growth is being driven by multiple forces at once, which is why the trend has so much momentum. Any one of these factors alone would push some volume out of hospitals. Combined, they are creating a structural shift in where surgery happens in America.

CMS Payment Policy

The Centers for Medicare and Medicaid Services has been systematically adding higher-acuity procedures to the ASC Covered Procedures List. Total knee arthroplasty was added in 2020. Total hip arthroplasty followed. Certain spine procedures, including some lumbar fusions, are now approved for ASC settings. Each addition opens a new revenue stream for ASCs and a new exit ramp for surgeons who want to move cases out of hospitals.

CMS pays ASCs less than it pays hospital outpatient departments for the same procedure — roughly 55-60% of the HOPD rate in many cases. But ASC overhead is dramatically lower than hospital overhead, so the margin can actually be better for the facility and the surgeon, even at lower reimbursement. The math works, and everyone involved can do the math.

Surgeon Economics

When an orthopedic surgeon performs a total knee replacement at a hospital, the surgeon collects a professional fee. The facility collects a facility fee. The surgeon has no economic interest in how efficiently the facility operates, how much it pays for implants, or how many cases it runs per day.

When that same surgeon performs the same procedure at an ASC they own or have equity in, they collect their professional fee and a share of the facility profit. Suddenly, every dollar saved on implant cost, every minute shaved off turnover time, and every additional case squeezed into the schedule directly increases the surgeon’s income. This alignment of clinical and financial incentives is the single most powerful driver of the ASC model.

Patient Preference

Patients prefer ASCs. Shorter wait times, dedicated surgical staff, no exposure to the general hospital patient population, and in most cases, a more efficient and less intimidating experience. Patient satisfaction scores at ASCs consistently outperform hospital outpatient departments. In competitive orthopedic markets, offering an ASC option is a patient acquisition tool.

Private Equity Investment

PE firms have identified ASCs as an attractive asset class: predictable revenue, high margins, scalable operations, and a regulatory tailwind. Major ASC management companies — USPI (Tenet), SCA Health (UnitedHealth Group/Optum), Surgery Partners — are actively acquiring and building centers. Physician-led development groups are also building new ASCs, sometimes in partnership with PE capital. The investment money accelerates growth, professionalizes operations, and in many cases, applies purchasing pressure that directly affects device pricing.

Advances in Anesthesia and Pain Management

The clinical ability to perform major orthopedic procedures in an outpatient setting depends on advances in regional anesthesia, multimodal pain protocols, and rapid recovery pathways that did not exist 15 years ago. Adductor canal blocks, periarticular injections, and spinal anesthesia techniques have made same-day discharge after total joint replacement clinically safe for appropriately selected patients. Without these advances, CMS would not have approved these procedures for ASCs, and surgeons would not attempt them.

Which Procedures Are Moving to ASCs

Not every surgical procedure is a candidate for ASC migration. The procedures moving fastest share common characteristics: predictable surgical time, manageable pain control, low complication rates, and patients who can safely recover at home with minimal monitoring.

Orthopedic Procedures Leading the Migration

• Arthroscopic procedures. These moved to ASCs years ago and are now overwhelmingly performed in outpatient settings. Knee arthroscopy, shoulder arthroscopy (rotator cuff repair, labral repair, subacromial decompression), hip arthroscopy, and ankle arthroscopy are ASC staples.
• Total and partial knee arthroplasty. The fastest-growing category of ASC orthopedic volume. Healthy patients under 75 with BMI under 40 and no major comorbidities are increasingly having knee replacements as same-day surgery.
• Total hip arthroplasty. Following the same trajectory as knee replacement, with anterior approach hip replacement particularly suited to ASC settings because of its typically faster recovery.
• Hand, wrist, and upper extremity procedures. Carpal tunnel release, trigger finger release, distal radius fracture fixation, and small joint arthroplasty are routine ASC cases.
• Foot and ankle procedures. Bunionectomy, hammertoe correction, ankle arthroscopy, and Achilles repair are well-established ASC procedures.
• Fracture fixation. Selected fracture fixation cases — particularly upper extremity — are being done in ASCs, though this remains more limited due to trauma scheduling unpredictability.

Spine Procedures Entering the ASC Space

• Single-level lumbar microdiscectomy and laminectomy. These have been done in ASCs for years.
• Anterior cervical discectomy and fusion (ACDF). Single-level and select two-level ACDFs are increasingly performed in ASCs with same-day discharge.
• Minimally invasive lumbar fusion. Select single-level MIS TLIF and LLIF procedures are being performed at ASCs in certain markets, though this remains at the leading edge.

The common thread across all of these is that the industry trends are pointing toward more procedures, not fewer, moving to the ASC setting over the next five years. The question for device sales professionals is not whether to sell into ASCs. It is how to sell into ASCs effectively.

How ASC Purchasing Differs from Hospital Purchasing

If you have been selling medical devices primarily to hospitals, ASC sales will feel like a different business. Because in several important ways, it is.

Decision-Making Speed

Hospitals have value analysis committees, product standardization processes, contracting departments, and approval workflows that can take months. Getting a new product approved at a large health system can take 6-18 months from first presentation to first case.

At a surgeon-owned ASC, the decision-maker is often the surgeon who will use the product, the administrator who manages the business, and one or two partners. A product decision that takes a hospital a year can happen at an ASC in a week. You present the product, the surgeon evaluates it, the administrator checks the price against reimbursement, and you get a yes or no. This speed is an enormous advantage for reps who can move quickly and come prepared.

Price Sensitivity

ASCs are more price-sensitive than hospitals on implants and supplies, and the sensitivity is rational, not arbitrary. When the surgeon owns the facility, every dollar of implant cost comes directly out of their profit. Hospital-employed surgeons often have no idea what the implants they use cost. Surgeon-owners know to the penny.

This does not mean ASCs always buy the cheapest product. It means they buy the product that delivers the best value — clinical performance relative to cost. If a $3,000 knee system produces outcomes equivalent to a $5,500 system, the ASC will use the $3,000 system unless there is a compelling clinical reason not to. Reps who can demonstrate value — not just features, but economic value — win in this environment.

GPO Influence Is Lower

Many ASCs do not participate in Group Purchasing Organization contracts, or they participate selectively. Hospital systems often mandate GPO contracts that lock in specific product lines across the entire system. ASCs, especially physician-owned ones, frequently negotiate directly with distributors and manufacturers. This creates more opportunity for independent distributors and reps who can offer competitive pricing without the GPO overhead.

Relationships Are More Personal

In a 200-bed hospital, you might interact with the surgeon, the OR director, the materials manager, the VAC committee, and the supply chain department. At a four-OR ASC, you interact with the surgeon and the administrator. Maybe the same person. The relationship is closer, more direct, and more personal. Your reliability, responsiveness, and likability matter more because there are fewer layers between you and the decision.

The Surgeon-Ownership Factor

The single most important thing to understand about the ASC market is that surgeons are often the owners. This changes everything about how you sell, what you sell, and how you maintain the account.

When a surgeon owns the ASC, they think about their practice in two dimensions simultaneously: clinical outcomes and facility profitability. They want excellent implants that produce great patient results. They also want those implants at the lowest price that does not compromise quality, because every dollar of implant cost reduces their facility margin.

This creates a dynamic where the surgeon evaluates devices differently than they would in a hospital setting. In a hospital, a surgeon might prefer a premium implant system because they like the instrumentation, and they do not care that it costs $2,000 more than the alternative because the hospital is paying. In their own ASC, that same surgeon will seriously evaluate the less expensive system if the clinical performance is comparable.

For device reps, this means:

• You need to know the reimbursement for every procedure you support, not just the product price
• You need to show the surgeon their case profitability with your products vs. alternatives
• You need to help the ASC operate efficiently — faster turnover, fewer wasted supplies, better scheduling
• You need to be a business partner, not just a product vendor

What ASC Growth Means for Device Sales Reps

The migration of surgical volume from hospitals to ASCs creates both opportunities and threats for medical device sales professionals. Which one you experience depends on how you adapt.

The Opportunity

ASCs are growing the total addressable market for device sales. More facilities performing surgery means more customers, more cases, and more potential revenue. New ASC openings represent greenfield opportunities where product lines have not been established and purchasing patterns have not hardened.

For independent 1099 reps and distributors, ASCs are often more accessible than hospitals. The barriers to entry are lower. You do not need to get through a GPO contract and a VAC committee. You need to build a relationship with a surgeon and demonstrate value. This plays to the strengths of the independent device sales model.

The Threat

If your business is built on hospital accounts where you have established contracts and deep institutional relationships, ASC growth can erode your volume without you winning or losing a single account. Your surgeon simply starts doing cases at their ASC instead of at your hospital — and uses a different rep’s products at the ASC because that rep offered a better price and showed up first.

Hospital-based reps who ignore the ASC trend are watching their case volumes decline and attributing it to surgeon retirement or procedure mix changes. Often, the cases are not disappearing. They are moving across town to an ASC where someone else is covering them.

The Adaptation

The smartest reps are following their surgeons. If your surgeon is building or buying into an ASC, you need to be part of that conversation early. Offer to help with product selection for the new center. Bring a pricing structure that works for the ASC model. Be the first rep who shows up with solutions tailored to the outpatient setting rather than repackaged hospital offerings.

For those looking to enter medical device distribution, the ASC segment is arguably the best entry point in the market right now. New centers need everything — implants, biologics, instrumentation, disposables — and they need suppliers who understand their unique operating model.

Distribution and Logistics in the ASC Market

ASCs have different logistics requirements than hospitals, and meeting those requirements is a competitive differentiator for distributors.

Storage Constraints

Most ASCs have a fraction of the storage space available in a hospital. There is no large central supply warehouse. Storage rooms are small. This means ASCs cannot stock large consignment inventories the way hospitals do. They need just-in-time delivery — the right products arriving the day before or the morning of the case, with minimal excess.

Case-Based Delivery

The ideal logistics model for ASC supply is case-based: the distributor assembles the exact implants and instrumentation needed for each scheduled case and delivers them as a complete kit. This reduces the ASC’s inventory burden, minimizes waste, and ensures nothing is missing when the surgeon is ready to operate.

This model requires the distributor to have deep inventory, excellent communication with the surgical scheduler, and the logistical capability to deliver precisely on time. Zero lead time is not a marketing tagline in the ASC market. It is an operational requirement.

Instrument Tray Management

ASCs typically do not have the sterile processing capacity of a large hospital. Many have a single autoclave and limited decontamination space. This means instrument trays need to arrive sterile or with enough lead time for processing between cases. Distributors who provide loaner trays need to ensure they arrive clean, complete, and on time — every time. One missing instrument or one late tray delivery can shut down an OR and cost the ASC thousands in lost revenue.

Pricing and Margin Dynamics

Implant pricing in the ASC market is lower than hospital pricing. This is not a secret, and fighting it is a losing strategy. The question is how to build a profitable business at ASC price points.

ASC implant pricing for total joint components typically runs 30-50% below hospital pricing for comparable products. Spine hardware pricing is similarly discounted. Biologics pricing varies but generally follows the same downward pattern in ASC settings.

The offset for distributors and reps is volume and efficiency. ASCs run tighter schedules with less downtime. Case coverage is more predictable. Logistics are simpler (one delivery location, consistent scheduling). Administrative overhead is lower (fewer forms, fewer committees, faster payment cycles). If you can operate efficiently in the ASC segment, the lower per-case revenue can be offset by lower per-case cost of doing business.

For independent reps, the commission structure matters. Make sure your distribution agreements account for the reality of ASC pricing. A 25% commission on a $6,000 hospital knee system generates $1,500. A 25% commission on a $3,500 ASC knee system generates $875. You need more volume, lower operating costs, or higher commission rates to make the math work at ASC pricing.

How to Win ASC Business

Winning and keeping ASC accounts requires a specific approach. Here is what works.

• Lead with economics. Show the surgeon-owner exactly what their per-case profitability looks like with your products. Bring a spreadsheet, not a brochure.
• Demonstrate logistics reliability. ASCs cannot absorb supply chain failures the way hospitals can. They do not have backup inventory. Prove that your distribution model delivers consistently, completely, and on time.
• Offer flexibility. ASCs want distributors who can accommodate schedule changes, handle add-on cases, and provide same-day support when needed. Rigidity kills ASC relationships.
• Bring operational value. Help the ASC run better. Suggest tray configurations that reduce setup time. Identify opportunities to reduce waste. Share best practices from other ASCs you serve. Be a partner in their operational success, not just a product supplier.
• Respect the surgeon’s dual role. When the surgeon is also the business owner, every conversation has a clinical and financial dimension. Be fluent in both.
• Show up early for new builds. The easiest time to win an ASC account is before it opens. Surgeons building new centers are selecting product lines, establishing vendor relationships, and setting up supply chain processes. Get into those conversations during the planning phase, not after the center is already running with a competitor’s products.

The ASC market is not a niche anymore. It is becoming the primary surgical venue for a growing list of orthopedic, spine, and sports medicine procedures. Medical device sales professionals who understand the ASC operating model, build relationships with surgeon-owners, and deliver consistent value at competitive pricing will capture a disproportionate share of the growth. Those who keep treating ASCs like small hospitals will keep losing to competitors who know the difference.

Frequently Asked Questions

How do ambulatory surgery centers decide which medical device suppliers to use?

ASCs, especially surgeon-owned ones, make purchasing decisions much faster and more directly than hospitals. The surgeon-owner typically drives the clinical product selection based on their training, experience, and preference. The administrator or business manager evaluates pricing against reimbursement to ensure the facility makes a profit on each case. GPO contracts play a smaller role than in hospitals — many ASCs negotiate directly with distributors. The decision usually comes down to three factors: clinical quality of the product, price relative to reimbursement, and reliability of the rep and distributor supporting the product. A strong personal relationship with the surgeon and a demonstrated ability to deliver on time, every time, are often the deciding factors.

What is the biggest challenge for medical device reps selling to ASCs?

Pricing pressure. When surgeons own the facility, they are acutely aware of implant costs and how those costs affect their per-case profitability. Reps accustomed to hospital pricing find that ASCs demand 30-50% lower pricing on comparable products. The challenge is maintaining a profitable commission structure at these lower price points while delivering the same level of service, case coverage, and logistics support. Reps who succeed in the ASC market do so by increasing volume, reducing their per-case cost of operations, and positioning themselves as business partners who help the ASC optimize its overall financial performance — not just as product vendors negotiating price.

Are ASCs a good market for independent 1099 medical device reps?

ASCs are arguably the best market segment for independent reps right now. The barriers to entry are lower than in hospitals because there are fewer institutional gatekeepers (no VAC committees, less GPO lock-in). Decision cycles are shorter. Surgeon relationships carry more weight. And new ASC openings create constant greenfield opportunities where product lines have not been established. Independent reps who can offer competitive pricing, reliable logistics, and strong clinical support are well-positioned to win ASC business that might be inaccessible in the hospital market. The key is understanding that ASC economics are different and structuring your business accordingly.

Which medical device categories have the most growth potential in the ASC market?

Total joint implants (knee and hip) represent the largest growth opportunity because these high-value procedures are still in the early stages of migrating from hospitals to ASCs. Spine devices for outpatient fusion and decompression procedures are a fast-growing but smaller segment. Sports medicine implants (anchors, interference screws, fixation devices) are already a mature ASC category but continue to grow with procedure volume. Biologics — bone grafts, PRP systems, soft tissue matrices — are used across all of these specialties and represent a significant revenue opportunity in ASCs. Capital equipment including smaller robotic-assisted surgery platforms designed for ASC environments is an emerging category that will grow as the technology scales down in size and cost.